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Abstract
Objectives. Evidence regarding the cost-effectiveness of joint protection and hand exercises for the
management of hand OA is not well established. The primary aim of this study is to assess the cost-
effectiveness (cost-utility) of these management options. In addition, given the absence of consensus
regarding the conduct of economic evaluation alongside factorial trials, we compare different analytical
methodologies.
Methods. A trial-based economic evaluation to assess the cost-utility of joint protection only, hand ex-
ercises only and joint protection plus hand exercises compared with leaflet and advice was undertaken
over a 12 month period from a UK National Health Service perspective. Patient-level mean costs and
mean quality-adjusted life years (QALYs) were calculated for each trial arm. Incremental cost-effectiveness
ratios (ICERs) were estimated and cost-effectiveness acceptability curves were constructed. The base
case analysis used a within-the-table analysis methodology. Two further methods were explored: the at-
the-margins approach and a regression-based approach with or without an interaction term.
Results. Mean costs (QALYs) were £58.46 (S.D. 0.662) for leaflet and advice, £92.12 (S.D. 0.659) for joint
protection, £64.51 (S.D. 0.681) for hand exercises and £112.38 (S.D. 0.658) for joint protection plus hand
exercises. In the base case, hand exercises were the cost-effective option, with an ICER of £318 per
QALY gained. Hand exercises remained the most cost-effective management strategy when adopting
alternative methodological approaches.
Conclusion. This is the first trial evaluating the cost-effectiveness of occupational therapy-supported
approaches to self-management for hand OA. Our findings showed that hand exercises were the most
cost-effective option.
Key words: cost-effectiveness, cost-utility, hand osteoarthritis, factorial trial.
Introduction
Hand OA is a common condition that affects a large pro-
portion of the population aged 45 years and over [13].
OA places a strain on scarce resources; for example, in a
recent study, the total annual direct cost of OA in the USA
was estimated to be double that of similar patients who
did not have OA [4]. In the UK, the total health care cost of
OA is estimated at more than £1 billion (2010 prices) [5].
Symptoms of hand OA include pain, stiffness and limited
hand function [6] and common management approaches
include exercises, joint protection and topical agents for
pain relief [2, 7]. European League Against Rheumatism
(EULAR) guidelines recommend that joint protection and
hand exercises should be offered in the management of
hand OA [2]. However, until recently there has been lim-
ited evidence to support the clinical effectiveness and
cost-effectiveness of these management options [8, 9].
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A 2 2 multicentre factorial trial was conducted to de-
termine the effectiveness of joint protection and hand ex-
ercises for the management of hand OA. This trial design
allowed for a simultaneous investigation of joint protection
vs no joint protection and hand exercises vs no hand ex-
ercises [9]. In determining the cost-effectiveness of inter-
ventions, there is no consensus regarding how economic
evaluations should be carried out alongside factorial trials.
Recent research [10] has reported that economic evalu-
ations alongside factorial trials have been carried out
using a variety of methods, including within-the-table ana-
lysis, the at-the-margins approach and a regression-
based approach [11].
This study evaluates the cost-utility of joint protection
and hand exercises for the management of hand OA and
compares alternative methodological approaches for con-
ducting economic evaluation alongside factorial trials.
Methods
The health economic evaluation was carried out alongside
a multicentre 2 2 factorial randomized trial in older
adults with hand OA. Details of the trial methodology
have been published elsewhere [8, 9]. Adults aged 50
years and over who consented and who met the eligibility
criteria were randomly assigned to one of the four treat-
ment groups: leaflet and advice, joint protection only,
hand exercises only and joint protection plus hand exer-
cises. The primary clinical outcome of the trial was re-
sponse to treatment [Osteoarthritis Research Society
International (OARSI)/OMERACT responder criteria] at 6
months [9]. The trial on which the present study is
based was approved by the North West 7 Research
Ethics Committee UK (rec reference: 07/H1008/235) and
was monitored by an independent trial steering committee
and a data monitoring committee (trial registration number
ISRCTN 33870549).
The economic evaluation reported here took the form of
a cost-utility analysis from a UK National Health Service
(NHS) perspective, using quality-adjusted life years
(QALYs) as the measure of health benefit. QALYs take
into account the survival and quality of life of an individ-
ual—the focus here was on the potential for quality of life
gains from a reduction in hand pain and improvement in
hand functioning due to the intervention.
Data collection
Resource use and costs
Health care resource use data were obtained from partici-
pant responses to self-report questionnaires administered
at 6 and 12 months. Resource use data concentrated
on visits to health care professionals in primary and sec-
ondary care, medical investigations/interventions and pre-
scribed medications. Resource use obtained from
participant responses to the questionnaires were aggre-
gated to generate overall resource use over the 12-month
follow-up period. For the trial interventions, information
was collected on the number and grades of staff involved
and the equipment used to deliver each intervention, as
well as the number of sessions each participant attended.
In order to value health care resource use, unit costs
were obtained from a number of sources, including the
British National Formulary, Unit Costs of Health and
Social Care and NHS reference costs [1214] and were
applied to resource use items. To estimate the cost of
each intervention, unit costs associated with equipment
used for each intervention were obtained. For the purpose
of costing staff time associated with each intervention, we
used the average time of a session: 60 min for joint pro-
tection only and hand exercises only and 90 min for joint
protection plus hand exercises [8]. Since all participants in
this study received leaflet and advice, this cost was not
included in the analysis. Details of the unit costs applied to
resource use are presented in Table 1. All unit costs were
valued at 2010/2011 prices in UK pounds sterling.
Health outcomes
Quality of life was measured at baseline, 3, 6 and 12
months using the EuroQol five-dimensions questionnaire
(EQ-5D), a generic questionnaire measuring health-related
quality of life. The UK value set [15] was used to obtain
EQ-5D index scores from participant responses to the
EQ-5D questionnaire at each time point. These index
scores were then used to calculate total QALYs over the
12-month period for every individual, using the analytical
method described below.
TABLE 1 Unit cost of health care resource use data over
12 months
Health care resource
Unit cost,
2010/11
prices, £
Primary care contacts [13]
Doctor at practice 28.00
Nurse at practice 10.00
Nurse at home 13.00
Secondary care contacts [14]
Orthopaedic surgeon 70.00
Rheumatologist 81.00
Plastic surgeon 52.00
Physiotherapist 35.00
Occupational therapist 38.00
Intervention cost
Leaflet and advicea 28.00
Joint protection plus
hand exercises
64.17
Joint protection only 45.29
Hand exercises only 36.64
Prescribed medication [12] Participant specific
Medical investigations/
interventions [14]
Participant specific
Other health care staff Participant specific
aAll participants received the leaflet and advice. For this
reason, the costs associated with this intervention were
assumed to be zero and were not included in the analysis.
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Statistical analysis
The cost-utility analysis was carried out on an intention-
to-treat basis, with the aim to estimate the difference in
costs and QALYs between the four trial interventions;
the exact nature of treatment comparisons is dependent
on the methodological approach (discussed later in this
section). Missing EQ-5D scores and costs at one or
more of the time points were imputed using multiple
imputation [16]. For each participant included in the
study, a QALY score over the 12 month period was
estimated using the area under the curve approach
[17]. Total NHS costs over the 12 month period were
calculated by multiplying the resource items used by the
respective unit cost and summing over all items.
Differences in mean costs and QALYs between trial
arms were estimated, where appropriate (i.e. depending
on the adopted methodology). Incremental QALY esti-
mates were adjusted to control for imbalances in base-
line utility between the interventions of interest [18].
Incremental cost-effectiveness ratios (ICERs) were esti-
mated by dividing the difference in mean cost between
two treatments by the difference in mean QALYs. Non-
parametric bootstrapping was used to illustrate and quan-
tify uncertainty. Five thousand paired estimates of
mean differential costs and QALYs were estimated and
presented graphically on a cost-effectiveness plane. To
determine the probability of a treatment being deemed
cost effective compared with an alternative treatment, a
cost-effectiveness acceptability curve (CEAC) was con-
structed [19]. This shows the probability that an interven-
tion is cost effective, relative to the chosen comparator,
across a range of values that represent a decision maker’s
willingness to pay for an additional QALY. All the analyses
were carried out in STATA version 12 (StataCorp, College
Station, TX, USA) [20].
Alternative analytical approaches
Three methods were explored. Each method has been
used for the analysis of clinical outcomes in factorial
trials and recent evidence suggests that the methods
can also be applied in economic evaluation [10].
Within-the-table analysis
A within-the-table analysis assumes that the interven-
tions are mutually exclusive, i.e. the costs and effects
of joint protection are influenced by the inclusion of
hand exercises and vice versa, therefore each trial
arm is treated separately with this approach. This ap-
proach formed the base case analysis and involved
considering each treatment option individually.
Interventions were ordered in terms of increasing cost,
and cost and outcomes for each arm were compared
incrementally. The most cost-effective option was se-
lected based on the principles of dominance [where
an intervention is less costly and more effective than
the appropriate comparator(s)] and extended (weak)
dominance (where an intervention is ruled out if the
ICER is greater than that of a more effective interven-
tion) [21].
At-the-margins approach
This approach assumes that interventions are independ-
ent, i.e. the cost and outcomes of joint protection are not
affected by whether hand exercises are included or not
and vice versa. The approach also assumes that the ef-
fects of the treatments when used together are additive,
i.e. there is no interaction between treatments [11], and
this approach considers the factorial trial as two separate
two-arm trials [22]. For this analysis, cost and outcomes
associated with participants who received hand exercises
(alone or in combination with joint protection) were com-
pared with those who did not receive hand exercises.
Similarly cost and outcomes associated with participants
who received joint protection (alone or in combination with
hand exercises) were compared with those who did not
receive joint protection.
Regression approach
Two separate analyses were carried out for the regression
approach. First, it was assumed that there was no inter-
action between the treatments (joint protection and hand
exercises), therefore an interaction term was not included
in the regression model. The second analysis involved ac-
counting for interactions between joint protection and
hand exercises by including an interaction term in the re-
gression model. In both cases the estimates of incremen-
tal cost and QALYs associated with hand exercises and
joint protection were obtained from the regression output.
Results
Baseline characteristics
A total of 257 participants were randomized to one of the
four treatment arms. The average age across all treatment
groups was 66 years (S.D. 9.1) and 66% of participants
were female. The difference in baseline EQ-5D scores be-
tween treatment arms was not statistically significant.
Overall, the average baseline EQ-5D score across all
groups was 0.643. Full details of other baseline charac-
teristics can be found elsewhere [9].
Resource use and costs
Complete resource use data were available for 209 par-
ticipants (81%). Table 2 gives a breakdown of resource
use data by trial arm. Mean health care costs per partici-
pant by trial arm after imputation over the 12 month period
are presented in Table 3. The total mean cost associated
with leaflet and advice, joint protection only, hand exer-
cises only and joint protection plus hand exercises over
the 12 month period were £58.46, £92.12, £64.51and
£112.38, respectively.
Health outcomes
Overall, 71% of participants provided complete EQ-5D
responses at all time points, however, the majority of
those with missing data were missing just one EQ-5D
score. Table 4 reports imputed EQ-5D scores at each
time point and QALY scores at 12 months. EQ-5D
scores at 12 months were higher than the baseline
www.rheumatology.oxfordjournals.org 3
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TABLE 2 Mean resource use over the 12 month follow-up
Resource use
category
Leaflet
and advice
(n=50),
mean (S.D.)
Joint
protection
only (n=47),
mean
(S.D.)
Hand exercises
only (n=48), mean
(S.D.)
Joint protection
plus hand exercises
(n=52), mean (S.D.)
Primary care
General practitioner 0.16 (0.62) 0.30 (0.93) 0.25 (0.81) 0.60 (1.90)
Nurse 0.02 (0.14) 0.04 (0.20) 0.06 (0.43) 0.12 (0.70)
Secondary care
Orthopaedic surgeon 0.04 (0.20) 0.02 (0.15) 0.00 () 0.04 (0.28)
Rheumatologist 0.02 (0.14) 0.00 () 0.02 (0.14) 0.04 (0.28)
Plastic surgeon 0.02 (0.14) 0.00 () 0.00 () 0.00 ()
Physiotherapist 0.18 (1.27) 0.09 (0.58) 0.00 () 0.00 ()
Occupational therapist 0.2 (1.28) 0.11 (0.52) 0.00 (-) 0.08 (0.55)
Other health care staff 0.36 (0.88) 0.55 (1.43) 0.17 (0.66) 0.31 (1.00)
Prescribed medicationa 1.34 (2.81) 1.76 (4.10) 1.79 (4.16) 1.48 (3.39)
aMean number of prescribed drugs per patient.
TABLE 4 Mean EQ-5D scores and QALYs over 12 months for primary analysis
Health outcome
Leaflet and
advice (n=65),
mean (S.D.)
Joint protection
only (n=62),
mean (S.D.)
Hand exercises
only (n=65), mean
(S.D.)
Joint protection
plus hand exercises
(n=65), mean (S.D.)
EQ-5D (imputed)
Baseline 0.623 (0.26) 0.646 (0.25) 0.645 (0.21) 0.659 (0.26)
3 months 0.665 (0.24) 0.682 (0.17) 0.660 (0.22) 0.676 (0.24)
6 months 0.658 (0.25) 0.635 (0.25) 0.692 (0.18) 0.672 (0.24)
12 months 0.634 (0.22) 0.684 (0.19) 0.708 (0.18) 0.659 (0.27)
QALYs (imputed)
QALYs at 12 months 0.649 (0.21) 0.660 (0.19) 0.682 (0.16) 0.668 (0.23)
QALYs at 12 months,
predicted meana
0.662 (0.17) 0.659 (0.16) 0.681 (0.14) 0.658 (0.16)
aValues are predicted mean scores obtained from the multiple regression equation when controlling for baseline imbalances.
None of the differences in EQ-5D or QALYs between the trial arms were statistically significant (KruskalWallis test).
TABLE 3 Mean costs (in £) over the 12-month follow-up
Resource use
category
Leaflet and
advice (n=65),
mean (S.D.)
Joint protection
only (n=62),
mean (S.D.)
Hand exercises
only (n=65), mean
(S.D.)
Joint protection plus
hand exercises (n=65),
mean (S.D.)
Primary care 5.98 (17.31) 8.53 (23.48) 8.31 (20.63) 16.17 (52.36)
Secondary care 16.75 (92.47) 15.70 (68.48) 3.00 (11.67) 10.36 (34.93)
Other health care 34.79 (175.07) 21.08 (60.84) 15.47 (67.89) 20.64 (56.69)
Prescribed medication 0.94 (1.82) 1.53 (3.76) 1.11 (3.62) 1.04 (2.31)
Intervention 0 (0)a 45.29 (0) 36.64 (0) 64.17 (0)
Total cost 58.46 (264.68) 92.12 (111.11) 64.51 (77.06) 112.38 (94.14)
aAll participants received the leaflet and advice. For this reason, the costs associated with this intervention were assumed to
be zero and were not included in the analysis.
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scores in all treatment arms. With regard to overall
QALYs, the highest score over the 12-month period was
recorded in the hand exercises group, while the lowest
score was observed in the leaflet and advice group.
When differences in overall QALYs were adjusted for
baseline utility, hand exercises were still associated with
the highest QALY gain over the 12-month period and joint
protection plus hand exercises was associated with the
lowest QALYs.
Cost-utility analysis
Within-the-table analysis (base case)
Table 5 presents the costs and QALYs associated with
each of the four interventions arranged in ascending
order from the lowest to the highest cost. Joint protection
plus hand exercises and joint protection only were elimi-
nated from the analysis because they were strongly domi-
nated. A direct comparison between hand exercises and
leaflet and advice indicated that hand exercises were cost
effective, with an ICER of £318/QALY gained. The cost-
effectiveness plane is shown in Fig. 1A. Forty-nine per
cent of the bootstrapped replicates indicate that hand ex-
ercises were more costly and more effective than leaflet
and advice (north-east quadrant). Thirty-two per cent of
the replicates indicate that hand exercises were less
costly and more effective than leaflet and advice (south-
east quadrant). The CEAC (Fig. 1b) shows that at a thresh-
old of £20 000/QALY gained, hand exercises are asso-
ciated with an 80% chance of being cost effective.
At-the-margins approach
With this approach, joint protection was more costly and
less effective than no joint protection, and therefore
strongly dominated. Hand exercises were slightly more
expensive than no hand exercises (difference in cost of
£13.55) but were more effective. The resulting ICER was
£1506/QALY gained, indicating that hand exercises is a
cost-effective intervention (see supplementary Table S1,
available at Rheumatology Online). There was a 70%
chance of hand exercises being cost effective at a
£20 000 threshold (see supplementary Fig. S1, available
at Rheumatology Online).
Regression approach
When interactions were ignored, hand exercises were
cost effective, with an ICER of £1452/QALY gained, with
a 70% chance of hand exercises being cost effective at a
threshold of £20 000/QALY gained (see supplementary
Fig. S2, available at Rheumatology Online). Joint protec-
tion was strongly dominated by no joint protection. When
an interaction term was included in the regression model,
this resulted in an ICER of £318/QALY gained when hand
exercises were compared with no hand exercises, with an
80% chance of hand exercises being cost effective at the
£20 000/QALY threshold (see supplementary Fig. S2,
available at Rheumatology Online). Joint protection was
again more costly and less effective than no joint protec-
tion and therefore strongly dominated (see supplementary
Table S2, available at Rheumatology Online).
Discussion
We evaluated the cost-utility of joint protection and hand
exercises for the management of hand OA and compared
alternative methodological approaches for conducting
economic evaluation alongside factorial trials. The results
showed that hand exercises appear to be the most cost-
effective option for the management of hand OA and
remain cost effective regardless of the approach adopted
for the economic analysis. However, the strength of evi-
dence in favour of hand exercises varied with the analysis
method adopted. All analytical approaches showed hand
exercises to be the most cost-effective option, with ICERs
ranging from £318 to £1506/QALY gained. The identical
results obtained from the within-the-table approach and
regression with an interaction term were expected since
the inclusion of an interaction term in the regression model
allows the estimation of main effects of joint protection
and hand exercises while controlling for the interactions
between them. Comparable results obtained from the at-
the-margins approach and the regression without an inter-
action term have also been shown in a previous study [10]
In the UK, the National Institute for Health and Care
Excellence uses a cost-effectiveness threshold of be-
tween £20 000 and £30 000/QALY gained to determine
whether an intervention is cost effective [23], which indi-
cates that hand exercises are cost effective regardless of
the analytical approach adopted.
This is the first study to provide evidence on the cost-
effectiveness of these interventions for hand OA. In add-
ition, the analysis considers a 12 month period, which
allows for the identification of any longer-term impacts
on quality of life and health care resource use, and al-
though imputation was employed in the analysis, the
TABLE 5 Cost-utility analysis using within-the-table analysis
Intervention Mean cost, £ Mean QALYsa ICER
Leaflet and advice 58.46 0.662 —
Hand exercises only 64.51 0.681 £318/QALY gainedb
Joint protection only 92.12 0.659 Dominated by hand exercisesc
Joint protection plus hand exercises 112.38 0.658 Dominated by hand exercisesd
aValues are predicted mean scores obtained from the multiple regression equation when controlling for baseline imbalances.
bHand exercises vs leaflet and advice. cJoint protection vs hand exercises. dJoint protection plus hand exercises vs hand
exercises. ICER: incremental cost-effectiveness ratio; QALYs: quality-adjusted life years.
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rate of complete response to the health care resource use
questions and EQ-5D questionnaire was reasonably high.
Furthermore, the advantage of the factorial nature of the
trial allowed us to compare four different management
options within the same analysis. However, conducting
an economic analysis alongside a factorial trial leads to
a much reduced sample size for the base case health
economic analysis, with four treatment options to com-
pare. The majority of economic analyses alongside two-
arm trials are underpowered due to the sample size being
powered by differences in the primary clinical outcome
rather than economic data. Therefore economic analyses
alongside factorial trials are likely to have an even greater
degree of uncertainty in the cost and outcome data.
To the best of our knowledge, no other study has as-
sessed the cost-effectiveness of joint protection and hand
exercises in hand OA. The clinical results of the trial on
which the current analysis was based demonstrated that
joint protection was the most clinically effective manage-
ment strategy [9] at 6 months, although the between-
group differences were not sustained at 12 months. It is
important to note that the primary outcome measures dif-
fered between the clinical and cost-effectiveness studies,
as did the time period assessed, i.e. incremental cost per
QALY (with QALYs estimated using the EQ-5D) was the
primary outcome measure for the economic analysis over
12 months, whereas the OARSI/OMERACT responder
criterion over 6 months was the primary outcome measure
for the clinical evaluation. Recent research has highlighted
issues related to contradictory economic and clinical
results [24].
Few studies have compared methods for the economic
analysis of factorial trials, although results from recent
work have shown that methods used for the economic
analysis of factorial trials do matter and could change
the results of a study [10]. The analyses reported in this
article have demonstrated that the results were not altered
by adopting different approaches, but it is important to
point out that the results obtained in this study may not
be generalizable to another disease area or context.
Although the results showed that there was very little
difference in QALYs between the treatment arms, the
agreed approach in health economics is to conduct a
cost-effectiveness analysis, focussing on the joint estima-
tion of costs and outcomes [25] rather than choosing the
intervention of least cost. Therefore the results here favour
hand exercises as the most cost-effective approach. This
study raises the issue of the use of generic utility-based
quality of life measures such as the EQ-5D. Even though
generic measures are important in economic evaluation
[26], they have also been shown to be insensitive in certain
disease areas, such as patients with hearing impairment
[2730]. Previous studies have also shown that the EQ-5D
is not very sensitive to subtle changes in OA in other joint
sites [31]. The EuroQol group has now developed a five-
level EQ-5D [32], which may be more sensitive to changes
in this disease area.
As previously stated, there is still no consensus with
regard to methods for conducting economic evaluation
alongside factorial trials. In the clinical literature it has
been suggested that the at-the-margins approach
should only be used when interactions between treat-
ments are not significant [33]. For this study, interactions
between treatments were not significant, suggesting that
the at-the-margins approach would be appropriate.
However, it is possible that the study is not sufficiently
powered to detect interactions between treatments.
Problems associated with detecting interactions in factor-
ial trials have been discussed elsewhere [22] and there is a
need for further research into methods for the economic
analysis of factorial trials.
Clinical guidelines, largely based on clinician expert
consensus, recommend joint protection and hand exer-
cises for people with hand OA [2]. The clinical results of
the trial have demonstrated the clinical effectiveness of
joint protection compared with no joint protection at 6
months [9]. The economic analysis further adds to the
evidence base by demonstrating that hand exercises are
a cost-effective option for the management of hand OA
over a 12-month period. These findings therefore offer a
FIG. 1 Cost-effectiveness plane and CEAC for the comparison of hand exercises vs leaflet and advice
Based on within-the-table analysis: (A) cost-effectiveness plane for hand exercises vs leaflet and advice; (B) CEAC for
hand exercises vs leaflet and advice. CEAC: cost-effectiveness acceptability curve.
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choice for the patient and health professional in deciding
the best approach for the management of hand OA.
Rheumatology key messages
. European League Against Rheumatism guidelines
recommend joint protection and hand exercises
for the management of hand OA.
. Hand exercises may offer a cost-effective option for
the management of hand OA.
. A different methodological approach to economic
analysis of factorial trials may not lead to different
conclusions.
Supplementary data
Supplementary data are available at Rheumatology
Online.
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